Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

NCT01087294 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

85

Enrollment

NIH

Sponsor class

Conditions

Leukemia, B-cell
Lymphoma, Hodgkins
Lymphoma, Non-hodgkins
Lymphoma, B-Cell

Interventions

PROCEDURE: Allogeneic stem cell transplant
BIOLOGICAL: Anti-CD19-chimeric-antigen-receptor-transduced T cells
PROCEDURE: Leukapheresis

Sponsor

National Cancer Institute (NCI)